Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944203 | 0.92 | CTSS (0.40) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL13336763 | 0.89 | CTSS (0.37) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL313693 | 0.88 | CTSS (0.38) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL12951727 | 0.88 | CTSS (0.36) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL8008964 | 0.88 | NPC1 (0.37) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL874861 | 0.88 | CTSS (0.36) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL8005359 | 0.88 | CTSS (0.36) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3427399 | 0.87 | CTSS (0.39) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL883451 | 0.87 | CTSS (0.39) | MAPTKDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL3429820 | 0.86 | CTSS (0.37) | MAPTKDM4ENPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2018-04-05 | — | — | US | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9328108-B2 | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328108-B2 | Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150152098-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | JANSSEN PHARMACEUTICALS INC (US) | 2015-06-04 | — | — | US | disclosed |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | Janssen Pharmaceuticals, Inc. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8445430-B2 | Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus | ACHILLION PHARMACEUTICALS, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011113859-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | MAPT 4366/4885KDM4E 695/4885NPC1 2805/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | MAPT 2229/4885KDM4E 4062/4885NPC1 447/4885 |
| US-20150152098-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | CTRC, GTF3C4, TMPRSS4 | MAPT 3625/4885KDM4E 413/4885NPC1 735/4885 |
| US-20140235852-A1 | PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | CTRC, GTF3C4, CTSC | MAPT 4044/4885KDM4E 306/4885NPC1 970/4885 |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CTRC, HAVCR2, HGFAC | MAPT 2655/4885KDM4E 2006/4885NPC1 1509/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | MAPT 2229/4885KDM4E 4062/4885NPC1 447/4885 |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | MAPT 3727/4885KDM4E 4649/4885NPC1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.